GlassScriptPhysician profile
Sumit A Walia
NPI 1295963247
$10,463.79
in general payments reported to CMS, 2019-2025
36 companies · $2,381 in 2025
The $2,381 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $1,137 · 2021: $994 · 2022: $1,825 · 2023: $1,708 · 2024: $1,496 · 2025: $2,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,454 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,454.13 |
| Education | $130.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,864.28 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,430.14 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $817.92 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $757.60 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $534.47 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $362.85 | 2019-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $288.49 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $231.31 | 2023-2025 | Dupixent |
| Medtronic, INC. | $197.00 | 2025 | Interstim |
| Genzyme Corporation | $186.59 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $178.40 | 2019-2024 | Dificid |
| Ardelyx, INC. | $153.61 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $148.19 | 2020-2023 | Injectafer |
| Gilead Sciences, INC. | $136.68 | 2019-2025 | |
| Celltrion USA INC. | $134.61 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $124.84 | 2020 | |
| Nestle Healthcare Nutrition INC. | $112.72 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $103.62 | 2024-2025 | Zenpep |
| Pharmacosmos Therapeutics INC. | $92.60 | 2023-2025 | Monoferric |
| Madrigal Pharmaceuticals | $78.41 | 2025 | Rezdiffra |
| Pfizer INC. | $74.91 | 2019 | |
| Intercept Pharmaceuticals, INC. | $73.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $68.21 | 2023 | Andexxa |
| Ironwood Pharmaceuticals, INC | $63.37 | 2021-2024 | |
| Shire North American Group INC | $53.69 | 2019 | |
| Braintree Laboratories, INC. | $35.94 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.28 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $25.56 | 2020 | |
| Phathom Pharmaceuticals, INC. | $20.47 | 2025 | Voquezna |
| Novo Nordisk INC | $19.51 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $17.28 | 2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $13.35 | 2022 | |
| Amgen INC. | $12.05 | 2022 | |
| Bausch Health US, LLC | $11.81 | 2021 | |
| Endo Pharmaceuticals INC. | $10.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Walia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.